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Abstract
Background: Research on inequalities in cervical cancer screening (CCS) participation has overlooked the
distinction between ‘never-’ and ‘under-screeners’ while different socioeconomic and demographic determinants
may underlie ‘non-’ and ‘under-’ screening participation. This study examines socioeconomic and demographic
inequalities in never and under CCS participation. We compare cross-national prevalence and trends among these
two groups in Switzerland and Belgium, two countries with similar opportunistic CCS strategy but different
healthcare systems.
Methods: Data on 38,806 women aged 20–70 from the Swiss Health Interview Survey (1992–2012) and 19,019
women aged 25–64 from the Belgian Health Interview Survey (1997–2013), both population-based cross-sectional
nationally representative surveys, was analysed. Weighted adjusted prevalence ratios were estimated with
multivariate Poisson regressions.
Results: Over the studied period, never screening prevalence was about 15% in both Switzerland and Belgium and
under screening prevalence about 14.0%. Socioeconomic gradients were found among both never- and under-
screeners. Higher income women had lower never and under screening prevalence in Switzerland and a similar
gradient in education was observed in Belgium. Importantly, distinct socioeconomic and demographic
determinants were found to underlie never and under screening participation. Never screening was significantly
higher among foreign nationals in both countries and this association was not observed in under screening. Never
screening prevalence was lower among older age groups, while under screening increased with older age. Over
time, age inequalities diminished among never- and under- screeners in Switzerland while educational inequalities
increased among never-screeners in Belgium.
Conclusion: Findings revealed that determinants of screening inequalities differed among never- and under-
screeners and hence these should be addressed with different public health strategies. Crucially, socioeconomic
and demographic inequalities were more pronounced among never-screeners who appeared to face more
structural and persistent inequalities. Differences between the two countries should also be noted. The more liberal-
type Swiss healthcare systems appeared to shape income-related screening inequalities, while education appeared
to be a stronger determinant of never- and under-screening in Belgium.
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: vladimir.jolidon@unige.ch
1Institute of Sociological Research, University of Geneva, 40 Bd du
Pont-d’Arve, 1211 Genève 4, Switzerland
Full list of author information is available at the end of the article
Jolidon et al. BMC Public Health         (2020) 20:1517 
https://doi.org/10.1186/s12889-020-09619-z
Introduction
Cervical cancer (CC) ranks fourth worldwide for both
incidence and mortality [1]. Europe’s overall incidence
rate is 11.2 per 100,000 women per year, in age-
standardised rate by world population, and Switzerland
and Belgium’s incidence rates are lower than the Euro-
pean average with 3.8 and 7.8 per 100,000, respectively
[1]. CC is the cancer that can most effectively be pre-
vented by screening. It was shown that cervical cancer
screening (CCS), and particularly organised population-
based CCS, reduces both incidence and mortality [2–4].
CCS may have reduced CC incidence and mortality by
80% in different contexts [5]. The beneficial effects of
CCS are reflected in the low CC incidence and mortality
rates of countries which introduced effective CCS. For
example, Western Europe has an average CC incidence
rate of 6.8 per 100,000 women, whereas that of Central
and Eastern Europe, characterised by lower screening
coverage, is of 16.0 per 100,000 [6]. Hence, European
and international guidelines recommend that CCS
should be organised and population-based [5, 7].
Socioeconomic and demographic factors such as edu-
cation, income, age, nationality and marital status were
shown to be associated with adherence to CCS, and that
such disparities persisted over time [8–12]. However, to
our knowledge, few studies analysed the distinct social
and demographic characteristics of ‘never-’ and ‘under-’
screeners (those who never screened and those who did
screen but not within the 3-year recommendation
period) and previous research on CCS in Switzerland
and Belgium focused on women who screened within
the 3-year recommended period [11, 13].
This study addresses ‘never’ and ‘under’ CCS participa-
tion in Switzerland and Belgium using cross-sectional
data from the Swiss and Belgian national health inter-
view surveys spanning from 1992 to 2013. Comparing
two countries with similar CCS strategy but different
healthcare systems appeared to be particularly relevant.
That is, neither country has implemented CCS pro-
grammes (although Belgium’s Flemish region started a
CCS programme since 2013 [14]) and hence rely on op-
portunistic CCS. As opposed to organised CCS, oppor-
tunistic CCS leans on the individual’s awareness and
initiative to screen and on the doctor’s screening recom-
mendation to their patients. In both countries, it is
mainly the gynaecologist who recommends a CCS to
women during routine examinations [15, 16]. A cross-
national perspective on CCS is also relevant since most
cancer screening studies tended to focus on specific
countries [11, 14, 17].
The present study distinguishes between ‘never-’ and
‘under-screeners’ and hypothesises that these two groups
are affected by different socioeconomic determinants of
cancer screening participation. In contexts of
opportunistic CCS, we expect to find never and under
screening inequalities to persist over time in both
Switzerland and Belgium. We also expect to find differ-
ent patterns and trends of inequalities in CCS participa-
tion in the two countries since these vary across
contexts and are embedded in health systems. In sum,
this study aims to compare the prevalence and trends of
never and under CCS in Switzerland and Belgium and
investigate socioeconomic and demographic inequalities
and the trend of those inequalities over time.
Methods
Our study is based on data collected by the 1992–2012
Swiss Health Interview Survey (SHIS) and the 1997–
2013 Belgian Health Interview Survey (BHIS), both na-
tionally representative cross-sectional surveys compris-
ing five waves and based on a stratified random selection
of residents older than 14 years of age. The former was
implemented in 1992, 1997, 2002, 2007 and 2012, and
the latter in 1997, 2001, 2004, 2008 and 2013. The SHIS
study sample included women aged 20 to 70 years old
(N = 38,806) and that of the BHIS included women aged
25 to 64 years old (N = 19,019), based on each country’s
CCS age recommendation. After excluding respondents
who had missing data on the outcome variable, predic-
tors of interest and covariates, and had received cancer
treatment/ diagnosis in the past 12 months, 31,800
women were included in the SHIS final sample, and
9442 in the BHIS sample.
National contexts
The Swiss Law on Health Insurance mandated private
health insurances to reimburse one CCS every 3 years
for women from 18 to 69 years old since 1996 and the
Swiss medical guidelines advised to perform the Pap
smear test every 3 years on women aged 21–70 years
[18]. The Belgian cervical cancer screening policy
followed the European guidelines and recommended one
CCS every 3 years to 25–64 years old women [14].
Dependent and independent variables
Both the SHIS and the BHIS asked women if they ‘ever
had a Pap smear’ (yes, no) and, if they answered ‘yes’,
when was the last time they had it. The SHIS asked to
provide the month and year of the last Pap smear, while
the BHIS asked if the Pap smear was undertaken, ‘within
past 12 months, more than 1 year but not more than 2
years ago, more than 2 years but not more than 3 years
ago, more than 3 years but not more than 5 years ago,
and not within the past 5 years’. We computed two bin-
ary dependent variables to analyse women who ‘never-
screened’ (0 = ever screened, 1 = never screened), and
women who ‘under-screened’ (0 = screened within the
past 3 years, 1 = screened more than 3 years ago).
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Predictors of interest and covariates were selected based
on their potential association with CCS [9, 11, 16, 19]
and their availability in both the SHIS and BHIS. The
following predictors of interest were analysed: education
(primary, upper secondary, tertiary), monthly household
income (1st to 5th quintile), employment status
(employed, non-employed), partnership status (living,
not living with a partner/ spouse), nationality (national
citizen, foreign national), area of residence (urban, rural),
and age ranges (20–29, 30–39 …). Educational levels
followed the International Standard Classification of
Education 2011 [20]. Household income was weighted
according to the OECD-modified scale in both the SHIS
and BHIS (based on the number of adults and children
living in the household). Women who were unemployed,
at home, retired and out of the labour force were all
grouped in the non-employed category. Different age
ranges were applied to the SHIS and BHIS samples since
CCS recommendations differed in the two countries
(Switzerland 20 to 70 and Belgium 25 to 64 years old).
To control for potential associations with CCS screen-
ing, we included the following covariates in our analysis:
self-rated health (very good, good, fair, bad, very bad),
self-reported body mass index (underweight < 18.5 kg/
m2, normal weight 18.5 to < 25, overweight & obese 25
to ≥30), a doctor visit (general practitioner or any spe-
cialist) in the last 12 months (yes, no) and currently
smoking (yes, no). In the BHIS, the “doctor visit in the
last 12 months” included a dentist visit whereas it did
not in the SHIS.
Statistical analysis
In order to evaluate inequalities in never and under
CCS, adjusted prevalence ratios (APR) with 95% confi-
dence intervals (CI) were estimated with Poisson regres-
sion models and robust variance estimators. Such
models were shown to be adequate to analyse binary
outcomes, particularly with cross-sectional data, and eas-
ier to interpret and communicate with prevalence terms
as the measure of association [21, 22]. The two
dependent variables were analysed in separate models
and treated as binary variables. Models presented in
Table 2 and Tables S.3a and S.3b (supplementary mate-
rials) were adjusted for all the independent variables
mentioned above. Models presented in Table 2 analysed
data from pooled waves and were also adjusted for time
(survey wave variable). In order to evaluate the potential
time trend of our predictors of interest, we performed
one separate multivariate model for each of these with
an interaction term between the predictor and the sur-
vey wave variable, along with all independent variables.
The P-values of the interaction terms for time trend
were reported in Table 2. Descriptive statistics and re-
gression analyses were weighted for survey sampling and
performed with SPSS 25 and STATA 14. SHIS data were
also weighted for non-response bias, as detailed else-
where [23]. Collinearity between independent variables
was tested with variance inflation factors and did not re-
veal any potential collinearity. SHIS and BHIS analysis
were performed separately by the authors of this study
and results were subsequently compared and discussed.
Results
Participants’ characteristics
Swiss and Belgian samples are summarised in Table 1.
Some differences between the two samples were partly
due to the different age ranges applied; for example, in
the Swiss sample, less women achieved primary and ter-
tiary education and less women were in the first and sec-
ond household income quintiles compared to the
Belgian sample. In the Swiss sample, there was a higher
proportion of underweight women and foreign nationals,
and a lower proportion of women visited a doctor in the
last 12 months, compared to the Belgian sample.
Prevalence and trends in never and under cervical cancer
screening
Over the studied period, never CCS prevalence was
15.8% in Switzerland and 15.0% in Belgium (Table 1).
The prevalence increased in Switzerland by 6% (APR
1.06, 95%CI 1.04–1.09) and decreased in Belgium by
12% on average by survey wave (APR 0.88, 95%CI 0.84–
0.92) (Table 2). Under CCS prevalence was 13.0% in
Switzerland and 14.7% in Belgium. It increased in
Belgium by 7% (APR 1.07, 95%CI 1.02–1.13) in average
by survey wave and did not show a significant tendency
in Switzerland throughout the studied period (APR 1.01,
95%CI 0.98–1.04). Figures 1 and 2 show the prevalence
of never and under screening over time for both
Switzerland and Belgium.
Inequalities and trends in never and under cervical cancer
screening
Never screening
In both Switzerland and Belgium, never screening preva-
lence was lower among women with higher levels of
education, higher household incomes, living in couple
and from older age groups (Table 2). Prevalence was
higher among foreign nationals. In Switzerland, never
screening prevalence followed a gradient from the 3rd to
5th household income quintiles, i.e. the higher income,
the less women never screened. Never screening was
higher among women living in a rural area. As showed
by the time interaction term, prevalence significantly
fluctuated over the 5 waves for partnership status how-
ever no clear trend was observed (Table S.3a). The time
interaction term for age was also significant and the dif-
ference between the APRs of the 20–29 year-old women
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Table 1 Characteristics of eligible women in Switzerland (SHIS 1992–2012) and Belgium (BHIS 1997–2013) samplesa
Switzerland (women aged 20–70)
N = 31,800
Belgium (women aged 25–64)
N = 9442
N % N %
Main independent variables
Education
Primary & lower secondary 4716 15 2820 28.8
Upper secondary 21,070 66.7 2925 32.6
Tertiary 6014 18.4 3697 38.6
Monthly household income
1st quintile 7121 23.6 1723 16.2
2nd quintile 6233 20.9 1505 16
3rd quintile 6870 20.6 1776 19.4
4th quintile 6949 21.2 2061 23.1
5th quintile 4627 13.7 2377 25.3
Employment
Employed 20,611 64.9 5884 63.7
Unemployed/ non-employed 11,189 35.1 3558 36.3
Partnership status
Single, widow, divorced and separated (and dissolved partnership) 11,830 28.7 2759 24.1
Living with spouse/ partner 19,970 71.3 6683 75.9
Age
20–29 (CH)/ 25–29 (BE) 5097 18.7 1150 11.5
30–39 7593 24.1 2682 29.2
40–49 7066 23.4 2479 27.2
50–59 6025 17.9 2172 22.7
60–70 (CH)/ 60–64 (BE) 6019 15.9 959 9.4
Nationality
National citizen (Swiss / Belgian) 27,653 81.7 8493 93.2
Foreign national 4147 18.3 949 6.8
Area of residence
Urban 22,470 72.1 6988 72.4
Rural 9330 27.9 2454 27.6
Covariates
Self-rated health
Very good 9163 29.1 2403 25.9
Good 18,165 57.5 4833 52.6
Fair 3514 10.6 1798 17.9
Bad 808 2.3 339 3.1
Very bad 150 0.4 69 0.5
BMI
Normal weight 18,734 59.3 5538 58.4
Underweight 4502 14.2 425 4.3
Overweight & obesity 8564 26.6 3479 37.3
Doctor visit in the last 12 months
No 5117 16.2 1037 10.6
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and older age groups reduced from 1992 to 2012. In
Belgium, never screening prevalences followed an educa-
tion and income gradient as these diminished among
more educated and higher income women (Table 2). Na-
tionality and area of residence had a significant time
interaction term but did not show a clear trend (Table
S.3a). Education inequality also varied significantly
throughout the period, APRs were significant in 1997,
2008 and 2013 and the differences between educational
strata slightly increased in 2013. Non-employment also
had a significant time trend. At the beginning of the
period (1997–2001), non-employed women had a lower
never screening prevalence compared to employed
women (although APRs were not significant, see Table
S.3a, supplementary materials), and this tendency re-
versed from 2004 to 2013 with non-employment in-
creasing never screening prevalence.
Under screening
In both Switzerland and Belgium, under screening
prevalence was significantly associated and diminished
with 5th household income quintiles, upper secondary
education and living in couple (Table 2). Under screen-
ing prevalence increased with the increase of age. In
Switzerland, under screening prevalence significantly de-
creased following a gradient throughout the 3rd, 4th and
5th household income quintiles. Under screening preva-
lence increased with rural area of residence. Time fluctu-
ation for household income and age groups was
significant. Household income did not show a clear
trend and age groups showed a tendency as inequalities
between women aged 20–29 and older age groups re-
duced over time (see Table S.3b, supplementary mate-
rials). In Belgium, under screening prevalence followed a
gradient in education and significantly decreased from
upper secondary to tertiary education level. Predictors of
interest did not change over the studied period since
time interactions were not significant.
Discussion
This study examined trends of never and under CCS
prevalence, and socioeconomic and demographic in-
equalities, using five waves of the SHIS and BHIS. Over
the studied period, both countries had similar preva-
lences, about 15% of never screening and 14% of under
screening. Although these levels of ‘never’ and ‘under’
CCS participation are relatively low compared to other
European countries [24], socioeconomic inequalities
were observed as women with higher education and in-
come showed lower never screening prevalence in both
countries. These inequalities resembled those revealed in
other screening tests in other countries which also relied
on opportunistic screening [8, 25, 26]. The higher par-
ticipation in CCS of highly educated women could be
explained by their higher ‘health literacy’, a more future-
oriented attitude and better risk perception which favour
more preventive-focused health decision [27]. Addition-
ally, negative attitudes towards cancer screening among
lower socioeconomic participants could also be mediat-
ing the association between income and screening par-
ticipation [17].
Belgium showed a gradient of screening inequalities in
education and income levels among never-screeners
while this gradient was only evident for income in
Switzerland. We may advance that inequalities were
shaped by economic determinants in the more liberal-
type Swiss healthcare system. Although health insurance
is compulsory for all Swiss residents, patient’s healthcare
Table 1 Characteristics of eligible women in Switzerland (SHIS 1992–2012) and Belgium (BHIS 1997–2013) samplesa (Continued)
Switzerland (women aged 20–70)
N = 31,800
Belgium (women aged 25–64)
N = 9442
N % N %
Yes 26,683 83.8 8405 89.4
Smoking
No 22,582 71.8 6868 74.3
Yes 9218 28.2 2574 25.7
Dependent variables
Never had a CCS
Never 5093 15.8 1526 15.0
Ever 26,707 84.2 7916 85.0
Under-screening (subsample: CH: N = 25,680; BE: N = 7788)
Under-screening (overdue CCS) 3581 13.0 1124 14.7
Up-to-date CCS (within the past 3 years) 22,099 87.0 6664 85.3
aProportions are weighted for sampling strategy in the SHIS and BHIS, and also for non-response in the SHIS
SHIS Swiss Health Interview Survey, BHIS Belgian Health Interview Survey
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cost participation and high out-of-pocket payments
cause high healthcare forgoing particularly among those
with lower incomes [28]. The Swiss healthcare system
shortcomings in addressing health inequalities and
implementing more health prevention were already iden-
tified and partly attributed to the fragmented nature of
the Swiss public health system (with high autonomy of
the cantons), which remains an obstacle to coordinate
Table 2 Adjusted prevalence rations (APR) for never and under CCS among eligible women in Switzerland and Belgiuma
Never had a CCS in
Switzerland
(women aged 20–70)
N = 31,800
Never had a CCS in Belgium
(women aged 25–64)
N = 9442
CC under-screening in
Switzerland
(women aged 20–70)
N = 25,680
CC under-screening in Belgium
(women aged 25–64)
N = 7788
APR 95%
CI
P-values for trend
over 5 wavesb
APR 95%
CI
P-values for trend
over 5 wavesa
APR 95%
CI
P-values for trend
over 5 wavesb
APR 95%
CI
P-values for trend
over 5 wavesb
Education (ref: primary &
lower secondary)
0.723 0.018* 0.19 0.712
Upper secondary 0.66 0.61–
0.72
0.80 0.68–
0.93
0.90 0.81–
0.99
0.84 0.71–
0.99
Tertiary 0.66 0.59–
0.74
0.59 0.49–
0.70
0.90 0.79–
1.03
0.69 0.56–
0.85
Employment (ref:
employed)
0.162 0.001** 0.48 0.834
Unemployed/ non-
employed
0.97 0.90–
1.04
1.15 0.97–
1.35
1.03 0.95–
1.13
0.98 0.83–
1.17
Monthly household
income (ref: 1st quintile)
0.214 0.087 0.024* 0.949
2nd quintile 0.81 0.74–
0.89
0.74 0.62–
0.89
0.98 0.88–
1.10
0.87 0.69–
1.08
3rd quintile 0.82 0.75–
0.90
0.73 0.60–
0.89
0.90 0.81–
1.00
0.86 0.69–
1.07
4th quintile 0.78 0.71–
0.86
0.63 0.51–
0.78
0.84 0.75–
0.94
0.92 0.73–
1.16
5th quintile 0.75 0.67–
0.84
0.62 0.49–
0.79
0.80 0.70–
0.92
0.74 0.57–
0.95
Partnership status (ref: no
partner)
0.032* 0.126 0.994 0.843
Living with spouse/
partner (living in
couple)
0.71 0.66–
0.76
0.80 0.70–
0.92
0.82 0.76–
0.88
0.86 0.73–
1.00
Age (ref: CH: 20–29 / BE:
25–29)
0.033* 0.977 0.004** 0.524
30–39 0.54 0.49–
0.58
0.62 0.53–
0.74
1.57 1.27–
1.95
1.96 1.28–
3.01
40–49 0.38 0.35–
0.42
0.50 0.42–
0.60
2.70 2.20–
3.30
2.56 1.69–
3.88
50–59 0.39 0.35–
0.44
0.47 0.38–
0.58
3.95 3.23–
4.82
3.26 2.14–
4.97
CH: 60–70 / BE: 60–64 0.56 0.50–
0.62
0.55 0.43–
0.70
6.49 5.31–
7.92
5.18 3.34–
8.04
Nationality (ref: national
citizen)
0.368 0.048* 0.598 0.557
Foreign national 1.65 1.53–
1.78
1.54 1.30–
1.81
0.91 0.80–
1.03
1.15 0.86–
1.53
Area of residence (ref:
urban)
0.88 0.032* 0.705 0.329
Rural 1.14 1.07–
1.22
0.99 0.86–
1.14
1.19 1.11–
1.29
1.03 0.89–
1.20
SHIS / BHIS waves (ref:
wave 1)
1.06 1.04–
1.09
0.88 0.84–
0.92
1.01 0.98–
1.04
1.07 1.02–
1.13
APR Adjusted prevalence ratios. APR are weighted for sampling strategy in the SHIS and BHIS, and also for non-response in the SHIS. Variables used for
adjustment: self-rated health, body mass index, doctor visit in the last 12months, smoking
* = p < 0.05; ** = p < 0.01; *** = p < 0.001
a SHIS 1992–2012 and BHIS 1997–2013
b P-values for trend were estimated separately for each predictor of interest with multivariate models including the interaction term (between the predictor of
interest and the survey wave variable)
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healthcare at the national level [29]. This income gradi-
ent of screening inequalities persisted among under-
screeners in Switzerland suggesting that lower income
women might be foregoing preventive healthcare. As a
qualitative study in Switzerland pointed out, women
who faced financial hardship either perceived the screen-
ing cost to be an “issue” or an “unnecessary expense”,
particularly if they considered themselves to be “in good
health” [30].
In both countries, education and income inequalities
seemed to be less pronounced among under-screeners
compared to never-screeners. We hypothesise that
women who screened at least once were more
acquainted with prevention and screening and hence less
affected by socioeconomic barriers to screening. Among
under-screeners, more practical issues might constitute
barriers to screening, such as scheduling a doctor’s ap-
pointment during the working week. Conversely, among
never-screeners, socioeconomic barriers to undertake a
very first screening appeared to be stronger and more
persistent over time.
Older age reduced never screening prevalence in both
countries and so did living in couple. Women who are
in a partnership, and older women, are more likely to
visit a gynaecologist, either to conceive or for contracep-
tion, and we may expect them to undertake CCS at least
once, as they enter their reproductive period [11]. On
the other hand, our results interestingly revealed that
under screening increased among older women in both
countries. We may advance that, as they become older,
women start neglecting their routine screening, particu-
larly after repeated negative screens, or their doctors
may insist less on screening within the recommended
time. Qualitative studies suggested that CCS participa-
tion declines as women enter a life stage in which sexu-
ality and pregnancy are less central and visits to the
gynaecologist less frequent [30]. Older women are also
more likely to cite lower levels of concern with CC (or
lower perceived risk) and more likely to express embar-
rassment and fear of pain [31].
Based on our results, we suggest that never- and
under-screeners should be addressed with different strat-
egies. A study on CCS uptake in the United Kingdom
stressed that policy interventions should consider the
CCS non-participants’ heterogeneity of motivations and
attitudes. It showed that 51% of CCS non-participants
“intended to screen but were overdue” since they failed
to translate intention into action, and 28% were unaware
of screening [32]. Younger and more disadvantaged
women were more likely to be found among those
groups. We suggest that measures to reduce inequalities
in CCS should focus on never-screeners – with an effort
to tackle issues such as screening awareness among the
most disadvantaged – while interventions among under-
screeners should pay attention to the intention-
behaviour gap in order to improve participation (for ex-
ample, through reminders), access and practical issues
(such as in scheduling a doctor’s appointment), although
inequalities among under-screeners should not be
neglected.
In both countries, screening inequality between na-
tionals and foreigners was found among never-screeners,
although not among under-screeners which supports
our hypothesis that sociodemographic inequalities were
Fig. 1 “Never had a CCS” weighted prevalence among eligible women in Switzerland and Belgium1. 1 Swiss Health Interview Survey (SHIS) 1992–
2012 and Belgian Health Interview Survey (BHIS) 1997–2013; Adjusted APR for time: CH = 95%CI 1.04–1.09, and BE = 95%CI 0.84–0.92 (see Table 2).
Notes: CH = Switzerland; BE = Belgium
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stronger among never-screeners. Living in rural area in-
creased both never and under screening prevalence in
Switzerland, while such inequalities were not found in
Belgium. This is consistent with studies of other cancer
screening tests in Switzerland [33] which pointed out
that women living in a rural area might under-screen
while their urban counterparts are more likely to over-
screen [34, 35].
Over the studied period, never CCS prevalence in-
creased 6% in average by survey wave in Switzerland
while it decreased 12% by survey wave in Belgium.
Under screening did not show a clear tendency in
Switzerland and it increased 7% by survey wave in
Belgium. In Switzerland, Burton-Jeangros et al. [11] ob-
served a slight decrease of CCS prevalence, based on the
same dataset of the present study. Our results suggested
that this decrease stemmed from a slight increase of
never screening – rather than under screening – over
the same period. In Belgium, an invitation programme
was in place in Flanders from the mid 1990’s until the
early 2000’s and could have contributed to reducing
never screening. Nevertheless, no impact of sending invi-
tations on screening uptake was found [14].
Inequalities between age groups among both never-
screeners and under-screeners diminished in Switzerland
throughout the studied period. This may have been
caused by a cohort effect, i.e. by a generation of women
who started to screen more at a younger age than the
previous generation, and continued to do so as they be-
came older. In Belgium, we observed increasing
education-based inequalities among never-screeners over
time which were explained in previous studies by a
combination of under-screening among women with
lower education and over-screening among women with
higher education in a context of opportunistic screening
[13].
Reliance on opportunistic screening in Switzerland
and Belgium may have contributed to the persistence of
the CCS inequalities observed in our study. Studies
showed that opportunistic screening entailed higher
screening inequalities, inconsistent quality and ineffi-
ciencies such as over-screening [8, 36–38]. As a Swiss-
Belgian comparative study on screening overuse showed,
although declining, over-screening is persistent in both
countries [35]. An organised approach to CCS, with
quality assurance framework and strategies to improve
never and under-screeners’ participation, may minimise
the adverse effects of unequal screening and maximise
benefits from a public health and cost perspective [37,
39]. In Switzerland, a nation-wide CCS programme
would help tackle screening inequalities in the context
of a fragmented healthcare system which contributes to
reproducing health inequalities. In Belgium, the CCS
organised programme which was launched in Flanders
should be extended nationwide to avoid reinforcing re-
gional inequalities.
Limitations of our study are worth noting. The SHIS
and BHIS are cross-sectional surveys hence our results
do not measure whether individual respondents com-
plied or not across time with the 3-year recommended
screening interval. However, from an aggregated (popu-
lation) level perspective, our ‘under-screening’ variable
allowed us to account for the women who screened
‘more than 3 years ago’ (the ‘under-screeners’), as
Fig. 2 “Under-screening” weighted prevalence among eligible women in Switzerland and Belgium1. 1 Swiss Health Interview Survey (SHIS) 1992–
2012 and Belgian Health Interview Survey (BHIS) 1997–2013; Adjusted APR for time: CH = 95%CI 0.98–1.04, and BE = 95%CI 1.02–1.13 (see Table 2).
Notes: CH = Switzerland; BE = Belgium
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opposed to those who screened within the recom-
mended interval. We could not control for related pre-
ventive practices of HPV vaccination and HPV testing in
our models since this information was not available in
the SHIS and the BHIS (only the BHIS 2013 wave col-
lected information on HPV vaccine uptake). HPV vac-
cination programmes were implemented among
teenagers and young women in 2008 and 2010 in
Switzerland and Belgium respectively (2011 in the
French-speaking part of Belgium) [40, 41]. Consequently,
these could only have affected the CCS practices of the
youngest cohort of the SHIS’ and BHIS’ last wave (not-
ably, only 25 women aged 25–49 had the vaccine in the
BHIS 2013 wave) and, hence, influenced our results in a
negligible way. Regarding HPV testing, this test has a 5-
year recommended screening interval which is larger
than the one of Pap smear. GPs and gynaecologists
could have offered this test as an alternative to Pap
smear which may have affected our under-screening
measure. Nonetheless, CCS recommendation guidelines
were based on Pap smear as primary screening in both
countries during the studied period [14, 18]. Gynaecolo-
gists implemented Pap smear as part of the routine
check-up in both countries and HPV testing was not re-
imbursed by the health insurance in Switzerland, and
only partly in Belgium [14, 15, 42–44]. The effects of
HPV vaccination and testing on CCS practices are diffi-
cult to evaluate. However, our data did not show an in-
crease of under screening which would suggest that new
preventive techniques had supplanted Pap smear since
2008 in either country. We cannot account for the com-
plexity of national contexts and healthcare systems. The
healthcare system design (public and private mix), levels
of public health expenditures, density of general practi-
tioners, payment schemes for general practitioners and
specialists, insurance coverage, amount of private out-of-
pocket payments, accessibility of care, as well as cultural
and environmental factors, affect screening participation
and inequalities and may produce confounding despite
adjustments [12, 45, 46]. Self-reported CCS data may be
affected by recall bias. Studies showed that women fairly
correctly reported CCS uptake, however, they tend to re-
port their last CCS more recently than it actually took
place - a phenomenon described as “telescoping” - which
may cause over-reporting of screening within a specific
timeframe and hence underestimation of under-
screening [47, 48]. Women may also over-report CCS by
recalling a routine gynaecologic exam without CCS as
including a CCS [47]. Additionally, social desirability
bias may lead to underestimates of never and under par-
ticipation or time since last screening test [47] and re-
sponse bias might also affect the data since women with
higher education level tend to report screening partici-
pation more often [49]. In spite of the SHIS and BHIS
representativeness limitations, the use of the weighting
factors allowed for inference from the sample to the
total population of Switzerland and Belgium. Finally, fur-
ther research is needed to inquire the motivations and
attitudes which lie behind ‘never’ or ‘under’ screening
participation in order to design policy interventions.
Conclusion
Screening inequalities among never- and under-
screeners persisted over time in both Switzerland and
Belgium and socioeconomic and demographic determi-
nants of screening inequalities differed between these
groups. Inequalities appeared to be more pronounced
amongst never-screeners compared to under-screeners
hence results stressed that the two groups should be ad-
dressed with different strategies. Differences were
highlighted between the two countries. Inequalities ap-
peared to be shaped by economic determinants in the
more liberal-type Swiss healthcare system, as showed by
the income gradient among never- and under-screeners,
while inequalities followed an education gradient in
Belgium. Finally, both Switzerland and Belgium could
benefit from an organised approach to CCS in order to
mitigate the screening inequalities observed in our study
and improve efficiency from a public health perspective.
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